[go: up one dir, main page]

WO2006030304A3 - Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof - Google Patents

Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof Download PDF

Info

Publication number
WO2006030304A3
WO2006030304A3 PCT/IB2005/002754 IB2005002754W WO2006030304A3 WO 2006030304 A3 WO2006030304 A3 WO 2006030304A3 IB 2005002754 W IB2005002754 W IB 2005002754W WO 2006030304 A3 WO2006030304 A3 WO 2006030304A3
Authority
WO
WIPO (PCT)
Prior art keywords
fluvastatin sodium
processes
pharmaceutical compositions
preparation
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002754
Other languages
French (fr)
Other versions
WO2006030304A2 (en
Inventor
Shantanu De
Vinayak Tripathi
Swargam Sathyanarayana
Shantanu Jindal
Yatendra Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2006030304A2 publication Critical patent/WO2006030304A2/en
Publication of WO2006030304A3 publication Critical patent/WO2006030304A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are substantially amorphous fluvastatin sodium and amorphous Form R6 and R-14 of fluvastatin sodium. Also provided are crystalline forms of fluvastatin sodium designated as Forms R-1, R-2, R-3, R-4, R-5, R-7, R-8, R-9, R-10, R-11, R-12, R-13, R-15 and R-16 and an anhydrous crystalline form. Also provided are processes for preparing such polymorphic forms and pharmaceutical compositions thereof. Also provided are methods for antagonizing HMG-CoA comprising administering to a mammal therapeutically effective amounts of the compounds described herein.
PCT/IB2005/002754 2004-09-17 2005-09-16 Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof Ceased WO2006030304A2 (en)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
IN1766/DEL/2004 2004-09-17
IN1766DE2004 2004-09-17
IN1848DE2004 2004-09-27
IN1848/DEL/2004 2004-09-27
IN1956DE2004 2004-10-11
IN1958/DEL/2004 2004-10-11
IN1958DE2004 2004-10-11
IN1956/DEL/2004 2004-10-11
IN2172DE2004 2004-10-29
IN2172/DEL/2004 2004-10-29
IN2170/DEL/2004 2004-10-29
IN2168/DEL/2004 2004-10-29
IN2168DE2004 2004-10-29
IN2170DE2004 2004-10-29
IN428/DEL/2005 2005-02-28
IN428DE2005 2005-02-28
IN1703/DEL/2005 2005-06-30
IN1703DE2005 2005-06-30

Publications (2)

Publication Number Publication Date
WO2006030304A2 WO2006030304A2 (en) 2006-03-23
WO2006030304A3 true WO2006030304A3 (en) 2006-12-07

Family

ID=35427294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002754 Ceased WO2006030304A2 (en) 2004-09-17 2005-09-16 Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof

Country Status (1)

Country Link
WO (1) WO2006030304A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2613021A1 (en) 2003-06-18 2004-12-29 Teva Pharmaceutical Industries Ltd Fluvastatin sodium crystal form lxxx, processes for preparing, compositions and methods of using
CA2583312A1 (en) * 2004-10-05 2006-04-13 Biocon Limited Process for the preparation of amorphous fluvastatin sodium
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
EP1904444A2 (en) * 2006-02-27 2008-04-02 Teva Pharmaceutical Industries Ltd Fluvastatin sodium novel forms and preparation therof
CN100429202C (en) * 2006-06-30 2008-10-29 浙江新东港药业股份有限公司 A kind of preparation method of amorphous fluvastatin sodium
ES2321571B1 (en) * 2007-07-18 2010-03-11 Ercros Industrial, S.A. SOLVATOS DE FLUVASTATINA SODICA AND ITS USE AS INTERMEDIATE IN OBTAINING FLUVASTATINA SODICA AMORFA.

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US6124340A (en) * 1996-06-24 2000-09-26 Astra Aktiebolag Polymorphic compounds
US20030032666A1 (en) * 2001-08-03 2003-02-13 Van Der Schaaf Paul Adriaan Crystalline forms
WO2003018555A1 (en) * 2001-08-22 2003-03-06 Ciba Speciality Chemicals Holding Inc. Process for the preparation of indole derivatives
US20030166946A1 (en) * 2000-05-26 2003-09-04 Annemarie Wolleb Process for the preparation of indole derivatives and intermediates of the process
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
US20050032884A1 (en) * 2003-06-18 2005-02-10 Revital Lifshitz-Liron Eluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
WO2005019170A1 (en) * 2003-08-26 2005-03-03 Biocon Limited Novel process for preparation of 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl]-3, 5-dihydroxy-6-heptenoic acid sodium salt
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
WO2005080332A1 (en) * 2004-01-14 2005-09-01 Cadila Healthcare Limited Novel form of fluvastatin sodium
US20050209259A1 (en) * 2004-03-17 2005-09-22 Le Huang Novel anhydrous amorphous forms of rosuvastatin calcium, pitavastatin calcium and fluvastatin sodium

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US6124340A (en) * 1996-06-24 2000-09-26 Astra Aktiebolag Polymorphic compounds
US20030166946A1 (en) * 2000-05-26 2003-09-04 Annemarie Wolleb Process for the preparation of indole derivatives and intermediates of the process
US20030032666A1 (en) * 2001-08-03 2003-02-13 Van Der Schaaf Paul Adriaan Crystalline forms
WO2003018555A1 (en) * 2001-08-22 2003-03-06 Ciba Speciality Chemicals Holding Inc. Process for the preparation of indole derivatives
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
US20050032884A1 (en) * 2003-06-18 2005-02-10 Revital Lifshitz-Liron Eluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
WO2005019170A1 (en) * 2003-08-26 2005-03-03 Biocon Limited Novel process for preparation of 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl]-3, 5-dihydroxy-6-heptenoic acid sodium salt
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
WO2005080332A1 (en) * 2004-01-14 2005-09-01 Cadila Healthcare Limited Novel form of fluvastatin sodium
US20050209259A1 (en) * 2004-03-17 2005-09-22 Le Huang Novel anhydrous amorphous forms of rosuvastatin calcium, pitavastatin calcium and fluvastatin sodium

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
O. REPIC, K. PRASAD, G.T. LEE: "The Story of Lescol: From Research to Production", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 5, 2001, pages 519 - 527, XP002357640 *
TEMPKIN O ET AL: "Asymmetric Synthesis of 3,5-Dihydroxy-6(E)-heptenoate-containing HMG-CoA Reductase Inhibitors", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 53, no. 31, 4 August 1997 (1997-08-04), pages 10659 - 10670, XP004105948, ISSN: 0040-4020 *

Also Published As

Publication number Publication date
WO2006030304A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
BRPI0713923B8 (en) hydroxylated and methoxylated pyrimidyl cyclopentane compounds, pharmaceutical composition comprising said compounds, method of preparing a compound, and use thereof
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
WO2005046662A3 (en) Hdl-boosting combination therapy complexes
CA2602643A1 (en) Composition for improving blood cholesterol levels
WO2008006093A3 (en) Estrogen receptor modulators and uses thereof
WO2006102674A3 (en) Diphenylheterocycle cholesterol absorption inhibitors
WO2008046087A3 (en) Spiro compounds and their uses as therapeutic agents
WO2008039829A3 (en) Diphenylheterocycle cholesterol absorption inhibitors
WO2006030304A3 (en) Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2006035277A3 (en) Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
WO2004075840A3 (en) Selective non-steroidal glucocorticoid receptor modulators
BRPI0510719A (en) naphthalimide derivatives, pharmaceutical composition, use and method of preparation thereof
WO2003007883A3 (en) Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
WO2008060372A3 (en) Thrombin receptor antagonists based on the modified tricyclic unit of himbacine
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
EP1106184A3 (en) Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
MY148499A (en) Substituted pyrrole derivatives
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
WO2007114902A3 (en) Alkylthiobenzylpiperidine compounds
WO2010038948A3 (en) Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
WO2006075139A3 (en) Novel process for the preparation of substituted indoles
WO2007114916A3 (en) Arylbenzylpiperidine compounds
JP2018521971A (en) Compounds or methods for modulating serotonin receptors in the periphery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase